Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells

Journal of Biological Chemistry

Volumn 289, Issue 5, 2014, Pages 2687-2700

  Singha, Bipradeb ^a   Gatla, Himavanth Reddy ^a   Manna, Subrata ^a   Chang, Tzu Pei ^a   Sanacora, Shannon ^a   Poltoratsky, Vladimir ^a   Vancura, Ales ^a   Vancurova, Ivana ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINES; CHROMATIN IMMUNOPRECIPITATION (CHIP); EGR-1; IMMUNOLOGY; INTERLEUKIN-8; NF-ΚB (NF-KB); OVARIAN CANCER; PROTEASOME; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL NUCLEUS; CHEMOKINE CCL2; CHEMOKINE CXCL5; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-8; MULTIPLE MYELOMA; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; TRANSCRIPTION FACTOR RELA;

EID: 84893444785     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.502641     Document Type: Article

References (73)

1. Xu, L., and Fidler, I. J. (2000) Interleukin 8. An autocrine growth factor for human ovarian cancer. Oncol. Res. 12, 97-106
2. Waugh, D. J., and Wilson, C. (2008) The interleukin-8 pathway in cancer. Clin. Cancer Res. 14, 6735-6741
3. Penson, R. T., Kronish, K., Duan, Z., Feller, A. J., Stark, P., Cook, S. E., Duska, L. R., Fuller, A. F., Goodman, A. K., Nikrui, N., MacNeill, K. M., Matulonis, U. A., Preffer, F. I., and Seiden, M. V. (2000) Cytokines IL-1, IL-2, IL-6, IL-8, MCP-1, GM-CSF, and TNF in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int. J. Gynecol. Cancer 10, 33-41
4. Milliken, D., Scotton, C., Raju, S., Balkwill, F., and Wilson, J. (2002) Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. 8, 1108-1114
5. Negus, R. P., Stamp, G. W., Hadley, J., and Balkwill, F. R. (1997) Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150, 1723-1734
6. Furuya, M., Suyama, T., Usui, H., Kasuya, Y., Nishiyama, M., Tanaka, N., Ishiwata, I., Nagai, Y., Shozu, M., and Kimura, S. (2007) Up-regulation of CXC chemokines and their receptors. Implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum. Pathol. 38, 1676-1687
7. Mukaida, N., Mahe, Y., and Matsushima, K. (1990) Cooperative interaction of NFκB- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J. Biol. Chem. 265, 21128-21133
8. Kunsch, C., and Rosen, C. A. (1993) NFκB subunit-specific regulation of the IL-8 promoter. Mol. Cell. Biol. 13, 6137-6146
9. Huang, S., Robinson, J. B., Deguzman, A., Bucana, C. D., and Fidler, I. J. (2000) Blockade of NFκB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of VEGF and IL-8. Cancer Res. 60, 5334-5339
10. Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Saito, M., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N, Sakata, M., Motoyama, T., Kurachi, H., Tasaka, K., and Murata, Y. (2004) Inhibition of NFκB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J. Biol. Chem. 279, 23477-23485
11. Annunziata, C. M., Stavnes, H. T., Kleinberg, L., Berner, A., Hernandez, L. F., Birrer, M. J., Steinberg, S. M., Davidson, B., and Kohn, E. C. (2010) NFκB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer 116, 3276-3284
12. Leizer, A. L., Alvero, A. B., Fu, H. H., Holmberg, J. C, Cheng, Y. C, Silasi, D. A., Rutherford, T., and Mor, G. (2011) Regulation of inflammation by the NFκB pathway in ovarian cancer stem cells. Am. J. Reprod. Immunol. 65, 438-447
13. Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N, Seino-Noda, H., Sakata, M., Motoyama, T., Kurachi, H, Testa, J. R., Tasaka, K., and Murata, Y. (2004) Inhibition of inhibitor of NFκB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin. Cancer Res. 10, 7645-7654
14. Chen, R., Alvero, A. B., Silasi, D. A., Kelly, M. G., Fest, S., Visintin, I., Leiser, A., Schwartz, P. E., Rutherford, T., and Mor, G. (2008) Regulation of IKKβ by miR-199a affects NFκB activity in ovarian cancer cells. Oncogene 27, 4712-4723
15. Hernandez, L., Hsu, S. C, Davidson, B., Birrer, M. J., Kohn, E. C, and Annunziata, C. M. (2010) Activation of NFκB signaling by inhibitor of NFκB kinase β increases aggressiveness of ovarian cancer. Cancer Res. 70, 4005-4014
16. Hsu, S., Kim, M., Hernandez, L., Grajales, V., Noonan, A., Anver, M., Davidson, B., and Annunziata, C. M. (2012) IKK-ε coordinates invasion and metastasis of ovarian cancer. Cancer Res. 72, 5494-5504
17. Hayden, M. S., and Ghosh, S. (2008) Shared principles in NFκB signaling. Cell 132, 344-362
18. Liu, F., Xia, Y., Parker, A. S., and Verma, I. M. (2012) IKK biology. Immunol. Rev. 246, 239-253
19. Smale, S. T. (2012) Dimer-specific regulatory mechanisms within the NF-κB family of transcription factors. Immunol. Rev. 246, 193-204
20. Natoli, G. (2012) NF-κB and chromatin. Ten years on the path from basic mechanisms to candidate drugs. Immunol. Rev. 246, 183-192
21. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., and Anderson, K. C (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076
22. Richardson, P. G., Mitsiades, C, Hideshima, T., and Anderson, K. C. (2005) Proteasome inhibition in the treatment of cancer. Cell Cycle 4, 290-296
23. McConkey, D. J., and Zhu, K. (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat. 11, 164-179
24. Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C, Munshi, N. C, Richardson, P. G., Carrasco, R. D., and Anderson, K. C. (2009) Bortezomib induces canonical NFκB activation in multiple myeloma cells. Blood 114, 1046-1052
25. Shah, J. J., and Orlowski, R. Z. (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23, 1964-1979
26. Kuhn, D. J., and Orlowski, R. Z. (2012) The immunoproteasome as atarget in hematologic malignancies. Semin. Hematol. 49, 258-262
27. Frankel, A., Man, S., Elliott, P., Adams, J., and Kerbel, R. S. (2000) Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 6, 3719-3728
28. Aghajanian, C, Dizon, D. S., Sabbatini, P., Raizer, J. J., Dupont, J., and Spriggs, D. R. (2005) Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J. Clin. Oncol. 23, 5943-5949
29. Ramirez, P. T., Landen, C. N. Jr., Coleman, R. L., Milam, M. R., Levenback, C., Johnston, T. A., and Gershenson, D. M. (2008) Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol. Oncol. 108, 68-71
30. Aghajanian, C, Blessing, J. A., Darcy, K. M., Reid, G., De Geest, K., Rubin, S. C, Mannel, R. S., Rotmensch, J., Schilder, R. J., Riordan, W., and Gynecologic Oncology Group. (2009) A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer. A Gynecologic Oncology Group study. Gynecol. Oncol. 115, 215-220
31. Jandial, D. D., Farshchi-Heydari, S., Larson, C. A., Elliott, G. I., Wrasidlo, W. J., and Howell, S. B. (2009) Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin. Cancer Res. 15, 553-560
32. Howell, S. B., Safaei, R., Larson, C. A., and Sailor, M. J. (2010) Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol. Pharmacol. 77, 887-894
33. Manna, S., Singha, B., Phyo, S. A., Gatla, H. R., Chang, T. P., Sanacora, S., Ramaswami, S., and Vancurova, I. (2013) Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells. The role of IKKa. J. Immunol. 191, 2837-2846
34. Vu, H. Y., Juvekar, A., Ghosh, C, Ramaswami, S., Le, D. H, and Vancurova, I. (2008) Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IκBα. Arch. Biochem. Biophys. 475, 156-163
35. Juvekar, A., Manna, S., Ramaswami, S., Chang, T. P., Vu, H. Y., Ghosh, C. C, Celiker, M. Y., and Vancurova, I. (2011) Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NFKB-dependent transcription and induction of apoptosis in CTCL. Mol. Cancer Res. 9, 183-194
36. Ghosh, C. C, Ramaswami, S., Juvekar, A., Vu, H. Y., Galdieri, L., Davidson, D., and Vancurova, I. (2010) Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IκBα. J. Immunol. 185, 3685-3693
37. Ramaswami, S., Manna, S., Juvekar, A., Kennedy, S., Vancura, A., and Vancurova, I. (2012) Chromatin immunoprecipitation analysis of NFκB transcriptional regulation by nuclear IκBα in human macrophages. Methods Mol. Biol. 809, 121-134
38. Saccani, S., Marazzi, I., Beg, A. A., and Natoli, G. (2004) Degradation of promoter-bound p65/RelA is essential for the prompt termination of the NFκB response. J. Exp. Med. 200, 107-113
39. Levêque, D., Carvalho, M. C., and Maloisel, F. (2007) Clinical pharmacokinetics of bortezomib. In Vivo 21, 273-278
40. Lee, C. M., Kumar, V., Riley, R. I., and Morgan, E. T. (2010) Metabolism and action of proteasome inhibitors in primary human hepatocytes. Drug Metab. Dispos. 38, 2166-2172
41. Powers, G. L., Ellison-Zelski, S. J., Casa, A. J., Lee, A. V., and Alarid, E. T. (2010) Proteasome inhibition represses ERα gene expression in ER+ cells. A new link between proteasome activity and estrogen signaling in breast cancer. Oncogene 29, 1509-1518
42. Gasparian, A. V., Guryanova, O. A., Chebotaev, D. V., Shishkin, A. A., Yemelyanov, A. Y., and Budunova, I. V. (2009) Targeting transcription factor NFκB. Comparative analysis of proteasome and IKK inhibitors. Cell Cycle 8, 1559-1566
43. Sakurai, H, Chiba, H., Miyoshi, H, Sugita, T., and Toriumi, W. (1999) IkB kinases phosphorylate NFκB p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem. 274, 30353-30356
44. Yemelyanov, A., Gasparian, A., Lindholm, P., Dang, L., Pierce, J. W., Kisseljov, F., Karseladze, A., and Budunova, I. (2006) Effects of IKK inhibitor PS1145 on NFκB function, proliferation, apoptosis, and invasion activity in prostate carcinoma cells. Oncogene 25, 387-398
45. Domingo-Domenech, J., Oliva, C, Rovira, A., Codony-Servat, J., Bosch, M., Filella, X., Montagut, C, Tapia, M., Campás, C, Dang, L., Rolfe, M., Ross, J. S., Gascon, P., Albanell, J., and Mellado, B. (2006) Interleukin 6, a NFκB target, predicts resistance to docetaxel in hormone-independent prostate cancer and NFκB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin. Cancer Res. 12, 5578-5586
46. Ma, J., Ren, Z., Ma, Y., Xu, L., Zhao, Y., Zheng, C, Fang, Y., Xue, T., Sun, B., and Xiao, W. (2009) Targeted knockdown of EGR1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR1/NFκB synergy. J. Biol. Chem. 284, 34600-34606
47. Hoffmann, E., Ashouri, J., Wolter, S., Doerrie, A., Dittrich-Breiholz, O., Schneider, H., Wagner, E. F., Troppmair, J., Mackman, N, and Kracht, M. (2008) Transcriptional regulation of EGR-1 by the interleukin-1-JNK-MKK7-c-Jun. pathway. J. Biol. Chem. 283, 12120-12128
48. Li, C., Chen, S., Yue, P., Deng, X., Lonial, S., Khuri, F. R., and Sun, S. Y. (2010) Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IκBα degradation. J. Biol. Chem. 285, 16096-16104
49. Anest, V., Hanson, J. L., Cogswell, P. C, Steinbrecher, K. A., Strahl, B. D., and Baldwin, A. S. (2003) A nucleosomal function for IkB kinase-α in NFαB-dependent gene expression. Nature 423, 659-663
50. Birbach, A., Gold, P., Binder, B. R., Hofer, E., De Martin, R., and Schmid, J. A. (2002) Signaling molecules of the NFκB pathway shuttle constitutively between cytoplasm and nucleus. J. Biol. Chem. 277, 10842-10851
51. Aguilera, C, Hoya-Arias, R., Haegeman, G., Espinosa, L., and Bigas, A. (2004) Recruitment of IKKα to the hes1 promoter is associated with transcriptional repression. Proc. Natl. Acad. Sci. 101, 16537-16542
52. Ear, T., Cloutier, A., and McDonald, P. P. (2005) Constitutive nuclear expression of the IkB kinase complex and its activation in human neutrophils. J. Immunol. 175, 1834-1842
53. Tsuchiya, Y., Asano, T., Nakayama, K., Kato, T. Jr., Karin, M., and Kamata, H. (2010) Nuclear IKKβ is an adaptor protein for IκBα ubiquitination and degradation in UV-induced NFκB activation. Mol. Cell. 39, 570-582
54. Espinosa, L., Bigas, A., and Mulero, M. C. (2011) Alternative nuclear functions for NFκB family members. Am. J. CancerRes. 1, 446-459
55. Sakamoto, K., Hikiba, Y., Nakagawa, H, Hirata, Y., Hayakawa, Y., Kinoshita, H., Nakata, W., Sakitani, K., Takahashi, R., Akanuma, M., Kamata, H, and Maeda, S. (2013) Promotion of DNA repair by nuclear IKKβ phosphorylation of ATM in response to genotoxic stimuli. Oncogene 32, 1854-1862
56. Buss, H, Dörrie, A., Schmitz, M. L., Hoffmann, E., Resch, K., and Kracht, M. (2004) Constitutive and IL-1-inducible phosphorylation of p65 NFκB at serine 536 is mediated by multiple protein kinases including IkB kinase (IKK)-α, IKKβ, IKKε, TRAF family member-associated (TANK)-binding kinase 1(TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated IL-8 transcription. J. Biol. Chem. 279, 55633-55643
57. Moreno, R., Sobotzik, J. M., Schultz, C, and Schmitz, M. L. (2010) Specification of the NFκB transcriptional response by p65 phosphorylation and TNF-induced nuclear translocation of IKK epsilon. Nucleic Acids Res. 38, 6029-6044
58. Sasaki, C. Y., Barberi, T. J., Ghosh, P., and Longo, D. L. (2005) Phosphorylation of RelA/p65 on serine 536 defines an IKBα-independent NFκB pathway. J. Biol. Chem. 280, 34538-345347
59. Jain, N., Mahendran, R., Philp, R., Guy, G. R., Tan, Y. H., and Cao, X. (1996) Casein kinase II associates with Egr-1 and acts as a negative modulator of its DNA binding and transcription activities in NIH 3T3 cells. J. Biol. Chem. 271, 13530-13536
60. Huang, R. P., Fan, Y., De Belle, I., Ni, Z., Matheny, W., and Adamson, E. D. (1998) Egr-1 inhibits apoptosis during the UV response. Correlation of cell survival with Egr-1 phosphorylation. Cell Death Differ. 5, 96-106
61. Barbolina, M. V., Adley, B. P., Ariztia, E. V., Liu, Y., and Stack, M. S. (2007) Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J. Biol. Chem. 282, 4924-4931
62. Bohuslav, J., Chen, L. F., Kwon, H, Mu, Y., and Greene, W. C (2004) p53 induces NFκB activation by an IkB kinase independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J. Biol. Chem. 279, 26115-26125
63. Wan, F., Anderson, D. E., Barnitz, R. A., Snow, A., Bidere, N., Zheng, L., Hegde, V., Lam, L. T., Staudt, L. M., Levens, D., Deutsch, W. A., and Lenardo, M. J. (2007) Ribosomal protein S3. A KH domain subunit in NFκB complexes that mediates selective gene regulation. Cell 131, 927-939
64. Wier, E. M., Neighoff, J., Sun, X., Fu, K., and Wan, F. (2012) Identification of an N-terminal truncation of the NFκB p65 subunit that specifically modulates ribosomal protein S3-dependent NFκB gene expression. J. Biol. Chem. 287, 43019-43029
65. Leung, T. H., Hoffmann, A., and Baltimore, D. (2004) One nucleotide in a kB site can determine cofactor specificity for NFκB dimers. Cell 118, 453-464
66. Natoli, G. (2006) Tuning up inflammation. How DNA sequence and chromatin organization control the induction of inflammatory genes by NFκB. FEBSLett. 580, 2843-2849
67. Hochrainer, K., Racchumi, G., and Anrather, J. (2013) Site-specific phosphorylation of the p65 protein subunit mediates selective gene expression by differential NFκB and RNA polymerase II promoter recruitment. J. Biol. Chem. 288, 285-293
68. Kunkel, S. L., Strieter, R. M., Chensue, S. W., Basha, M., Standiford, T., Ham, J., and Remick, D. G. (1990) Tumor necrosis factor-α, interleukin-8, and chemotactic cytokines. Prog. Clin. Biol. Res. 349, 433-444
69. Walz, A., Burgener, R., Car, B., Baggiolini, M., Kunkel, S. L., and Strieter, R. M. (1991) Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J. Exp. Med. 174, 1355-1362
70. Leonard, E. J., and Yoshimura, T. (1990) Human monocyte chemoattractant protein-1 (MCP-1). Immunol. Today 11, 97-101
71. Zerbini, L. F., Tamura, R. E., Correa, R. G., Czibere, A., Cordeiro, J., Bhasin, M., Simabuco, F. M., Wang, Y., Gu, X., Li, L., Sarkar, D., Zhou, J. R., Fisher, P. B., and Libermann, T. A. (2011) Combinatorial effect of non-steroidal anti-inflammatory drugs and NFκB inhibitors in ovarian cancer therapy. PLoS ONE 6, e24285
72. Murphy, M. A., Trabert, B., Yang, H. P., Park, Y., Brinton, L. A., Hartge, P., Sherman, M. E., Hollenbeck, A., and Wentzensen, N. (2012) Non-steroidal anti-inflammatory drug use and ovarian cancer risk. Findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control 23, 1839-1852
73. Valle, B. L., D'Souza, T., Becker, K. G., Wood, W. H., 3rd., Zhang, Y., Wersto, R. P., and Morin, P. J. (2013) Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. PLoS One 8, e61836